Your browser doesn't support javascript.
loading
Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect.
Satoh, Noriko; Ogawa, Yoshihiro; Usui, Takeshi; Tagami, Tetsuya; Kono, Shigeo; Uesugi, Hiroko; Sugiyama, Hiroyuki; Sugawara, Akira; Yamada, Kazunori; Shimatsu, Akira; Kuzuya, Hideshi; Nakao, Kazuwa.
Affiliation
  • Satoh N; Diabetes Center and Clinical Research Institute of Kyoto National Hospital, Kyoto, Japan.
Diabetes Care ; 26(9): 2493-9, 2003 Sep.
Article in En | MEDLINE | ID: mdl-12941708
OBJECTIVE: Thiazolidinediones (TZDs), a class of insulin-sensitizing agents used clinically to treat type 2 diabetes, are also antiatherogenic. This study was designed to elucidate the relationship between the antiatherogenic and antidiabetic effects of pioglitazone, a TZD, in type 2 diabetic patients. RESEARCH DESIGN AND METHODS: A total of 136 Japanese type 2 diabetic patients were included and divided into two groups: the pioglitazone-treated group (30 mg daily for 3 months) (n = 70) and the untreated control group (n = 66). The changes in glycolipid metabolism as well as plasma high-sensitivity C-reactive protein (CRP), leptin, adiponectin, and pulse wave velocity (PWV) were monitored to analyze the relationship between the antiatherogenic and antidiabetic effects of pioglitazone. RESULTS: The pioglitazone treatment significantly reduced hyperglycemia, hyperinsulinemia, and HbA(1c) levels and increased plasma adiponectin concentrations relative to the control group (P < 0.01). It also significantly decreased CRP and PWV (P < 0.01). The antiatherogenic effect was observed in both the nonresponders showing <1% of reduction in HbA(1c) (n = 30) and responders showing >1% of reduction (n = 40). ANCOVA revealed that treatment with pioglitazone was associated with a low CRP and PWV, independent of the changes in parameters related to glucose metabolism. CONCLUSIONS: This study represents the first demonstration of the antiatherogenic effect of pioglitazone in both nonresponders and responders with respect to its antidiabetic effect and suggests that pioglitazone can exert its antiatherogenic effect independently of its antidiabetic effect.
Subject(s)
Search on Google
Collection: 01-internacional Database: MEDLINE Main subject: Arteriosclerosis / Intercellular Signaling Peptides and Proteins / Thiazolidinediones / Diabetes Mellitus, Type 2 / Diabetic Angiopathies / Hypoglycemic Agents Type of study: Clinical_trials Limits: Female / Humans / Male / Middle aged Country/Region as subject: Asia Language: En Journal: Diabetes Care Year: 2003 Document type: Article Affiliation country: Japan Country of publication: United States
Search on Google
Collection: 01-internacional Database: MEDLINE Main subject: Arteriosclerosis / Intercellular Signaling Peptides and Proteins / Thiazolidinediones / Diabetes Mellitus, Type 2 / Diabetic Angiopathies / Hypoglycemic Agents Type of study: Clinical_trials Limits: Female / Humans / Male / Middle aged Country/Region as subject: Asia Language: En Journal: Diabetes Care Year: 2003 Document type: Article Affiliation country: Japan Country of publication: United States